Sepsis-associated Purpura Fulminans International Registry--Europe (SAPFIRE)

• Published in: Medizinische Klinik, Intensivmedizin und Notfallmedizin Intensivmedizin und Notfallmedizin, 2014-11, Vol.109 (8), p.591-595
• Main Authors: Brunkhorst, F M, Patchev, V
• Format: Article
• Language: ger
• Subjects: Critical Care; Cross-Sectional Studies; Europe; Hospital Mortality; Humans; International Cooperation; Multiple Organ Failure - etiology; Multiple Organ Failure - mortality; Multiple Organ Failure - therapy; Protein C Deficiency - complications; Protein C Deficiency - mortality; Protein C Deficiency - therapy; Purpura Fulminans - etiology; Purpura Fulminans - mortality; Purpura Fulminans - therapy; Registries - statistics & numerical data; Risk Factors; Sepsis - complications; Sepsis - mortality; Sepsis - therapy; Survival Analysis
• ISSN: 2193-6226
• DOI: 10.1007/s00063-014-0402-z

Purpura fulminans is a rare life-threatening condition which is characterized by disseminated thrombosis in dermal and systemic microcirculation, cutaneous hemorrhages with progressing necrosis and multiple organ failure. The underlying pathogenesis is based on the disruption of the intrinsic anticoagulation cascade, with protein C deficiency being considered the leading factor in this process. In the majority of cases, the condition emerges as consumptive coagulopathy associated with severe sepsis. Epidemiological data on sepsis-associated purpura fulminans (SAPF) are scarce and evidence-based treatment guidelines have not been established yet. While restoration of the balance in the coagulation cascade is a declared therapeutic goal, evaluations of the efficacy of different therapeutic approaches in randomized clinical trials are still lacking. The causal role of individual microbial pathogens also requires comprehensive evaluation. A prospective multicenter Sepsis-Associated Purpura Fulminans International Registry-Europe (SAPFIRE) will be established in the first quarter of 2015. For the first time, participating centers will systematically collect information on etiology, clinical course, biomarkers, treatment, morbidity, and mortality of SAPF. The SAPFIRE data will be periodically evaluated and disseminated. Retrospective analysis of each center's data and regular access to aggregated information collected by other centers will enable the participants to monitor and update care quality standards.